Abstract
Objectives To investigate the relationship between neuropsychiatric medication usage and COVID-19 outcomes before COVID-19 usage.
Methods This cross-sectional study used Optum’s de-identified Clinformatics® Data Mart Database to identify patients diagnosed with COVID-19 in 2020 and their psychiatric medication prescriptions in the United States. Ordered logistic regression was used to predict the likelihood of a higher COVID-19 severity level for long-term and new users. Results were adjusted for demographic characteristics and medical and psychiatric comorbidities.
Results Individuals taking all psychiatric medications were less likely to have a high severity score. Overall, users of psychiatric medications were less likely to have a higher severity score than those not taking any medications. Within individual classes, the results varied across long-term and short-term users.
Conclusions
Results of the current study suggest that psychopharmacological agents are associated with reduced COVID-19 severity levels. Specifically, our results show that antidepressant medications may be associated with a protective role against COVID-19. Considering the heightened risk of severe COVID-19 outcomes associated with depression and psychoses, early treatment with antidepressants and benzodiazepines could potentially lower the incidence of severe cases and mortality rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was submitted for review to UTHealth Houston IRB committee (IRB: HSC-SPH-20-0758). The committee determined to qualify for exempt status due to: Research, involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified directly or through identifiers linked to the subjects.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data cannot be shared publicly as it belongs to a third party, Optum. The Optum® Clinformatics® Data Mart (CDM) provides richly detailed longitudinal information through statistically de-identified patient data sourced from multiple sources. However, at the time of this submission, the researchers no longer have an active contract with Optum to access the data. Those interested in using the data must contact Optum directly to gain access.
